News
NERV
--
0.00%
--
These 3 Penny Stocks Could Double (Or More), Says BTIG
After an epic rally to all-time highs, the stock market has been seesawing between the red and the green. The volatility that has ensued wasn’t driven by overtly negative news; progress on a COVID-19 vaccine is being made and economic data has been better-than-expected.BTIG’s Julian Emanuel argues that
TipRanks · 09/14 15:20
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright
GlobeNewswire · 09/09 12:30
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15th Annual
GlobeNewswire · 09/02 12:30
Minerva Neurosciences shares are trading higher after the company reported Q2 earnings.
Benzinga · 08/03 12:29
Minerva Neurosciences Q2 EPS $0.75, May Not Compare To $(0.29) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $(0.29) by 358.62 percent. This is a 334.38 percent increase over losses of $(0.32) per
Benzinga · 08/03 11:36
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business update
GlobeNewswire · 08/03 11:30
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
Management to host conference callWALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,
GlobeNewswire · 07/27 12:00
Minerva Neurosciences Notified Its President, Rick Russell, That It Terminated His Employment Without Cause
-Reuters
Reuters · 07/02 20:27
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
GlobeNewswire · 07/01 13:00
Minerva Neurosciences Exercises Right To Opt Out Of Agreement With Janssen For Seltorexant (MIN-202)
Benzinga · 07/01 12:14
Hedge Fund Sentiment Is Stagnant On Minerva Neurosciences, Inc (NERV)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 06/27 19:17
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Zacks · 06/22 12:47
HC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to $10
HC Wainwright & Co. maintains Minerva Neurosciences (NASDAQ:NERV) with a Buy and lowers the price target from $20 to $10.
Benzinga · 06/08 10:37
Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session
Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Zacks · 06/05 13:05
Coronavirus Roundtable - Still Some Dancing To Be Done
Seeking Alpha - Article · 06/05 10:30
How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry
Zacks · 06/02 14:00
71 Biggest Movers From Yesterday
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares climbed 172.4% to close at $2.58 on Monday following earlier press release highlighting release of new thermal body temperature measurement camera, the V1100B-THM-TEMP.
Benzinga · 06/02 08:39
48 Stocks Moving In Monday's Mid-Day Session
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares jumped 198% to $2.8199.
Benzinga · 06/01 16:34
Mid-Morning Market Update: Markets Edge Higher; Zynga To Buy Mobile Game Developer Peak For $1.8B
Following the market opening Monday, the Dow traded up 0.15% to 25421.54 while the NASDAQ rose 0.35% to 9523.29. The S&P also rose, gaining 0.13% to 3048.20.
Benzinga · 06/01 14:18
MFGP, AAXN among premarket gainers
Seeking Alpha - Article · 06/01 13:18